No earnings catalyst — the stock remains a pure binary catalyst play on the Phase 3 ENSURE readout by end of 2026. The orderly leadership transition with proven MS commercial executives (Lundgren, Panzara) and the $155M cash runway de-risk execution risk modestly but do not change the asset-level odds. Watch for any safety or efficacy signals in upcoming scientific conferences before the ENSURE top-line data.
Price Chart
Executive Summary
Immunic reported Q2 2026 net loss of $34.1M ($0.80/share), roughly matching the Street consensus of -$1.24 (narrower loss on a per-share basis due to higher share count from the $200M PIPE). The net loss widened year-over-year from $26.8M, reflecting increased R&D ($25.9M vs $21.4M) and G&A ($9.4M vs $5.7M) spend ahead of the pivotal Phase 3 ENSURE readout expected by end of 2026. Cash of $155.1M funds operations into late 2027. Key events: founder/former CEO Daniel Vitt transitioned to a consulting role with a separation agreement; new CEO Erik Lundgren (ex-Roche/Genentech Ocrevus launch), new CMO Michael Panzara (ex-Sanofi/Biogen MS approvals), and new board member Elena Ridloff (CFO of Sionna) were appointed. The filing is neutral — pre-commercial biotech quarterly results are in line with expectations, and management changes are orderly and support the NDA/commercial readiness strategy.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $34.1M ($0.80/share) vs $26.8M ($2.03) in Q2 2025; share count tripled to 42.5M from 13.2M due to $200M PIPE closed Feb 2026.
- Cash and cash equivalents $155.1M as of June 30, 2026, providing runway into late 2027.
- Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track for top-line data by end of 2026; NDA submission targeted for mid-2027.
- Founder and former CEO Daniel Vitt resigned from board Aug 6, 2026; employment terminated Aug 7, 2026; to serve as consultant (12 months, 15h/month, €15k/month retainer) plus Chair of Scientific Advisory Board.
- New CEO Erik Lundgren appointed effective June 1, 2026 (ex-Genentech/Roche, led Ocrevus launch); new CMO Michael Panzara appointed April 24, 2026 (ex-Sanofi/Biogen, oversaw global approvals of Lemtrada, Aubagio, Tysabri); new board member Elena Ridloff appointed Aug 6, 2026.
- All of Daniel Vitt's outstanding equity awards vested as of the separation date; he has 3 years to exercise them.
- Non-competition restrictions for Vitt cover any Nurr1-activating or MS therapies for up to 18 months post-SAB service.
Financial Impact
Quarterly net loss widened $7.3M YoY to $34.1M; cash decreased $31.5M QoQ to $155.1M, consistent with pre-commercial burn rate.
Risk Factors
- Phase 3 ENSURE trial failure (relapsing MS) would eliminate >90% of pipeline value.
- Shareholder dilution: weighted-average shares rose from 13.2M to 42.5M YoY from the PIPE; further raises may be needed between NDA submission and commercial launch.
- Competing oral MS therapies (e.g. BMS's Zeposia, Novartis's Mayzent, and generics of teriflunomide/dimethyl fumarate) already on market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193805-26-001071 |
| Document: e665684_ex10-1.htm | 0001193805-26-001071 |
| Document: e665684_8k-immunic.htm | 0001193805-26-001071 |
| Document: e665684_ex99-1.htm | 0001193805-26-001071 |
| Document: 0001193805-26-001071-index-headers.html | 0001193805-26-001071 |
| Document: 0001193805-26-001071-index.html | 0001193805-26-001071 |
| Document: 0001193805-26-001071.txt | 0001193805-26-001071 |
| 8-K Data (Synthetic) | 0001193805-26-001071 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $12.19 | awaiting T+60 | — | $7.61 (−37.57%) |
Aug 11, 2026 11w ago | 8-K | $15.48 | awaiting T+60 | — | $7.61 (−50.84%) |
Jul 14, 2026 15w ago | 8-K | $14.69 $7.63 | ▼ −48.06% | ▼ −51.44% | $7.61 (−48.20%) |
Jun 29, 2026 17w ago | 8-K | $15.37 $9.37 | ▼ −39.04% | ▼ −42.60% | $7.61 (−50.49%) |
May 19, 2026 23w ago | 3 | $11.55 $16.06 | ▲ +39.05% | ▲ +34.04% | $7.61 (−34.11%) |
May 19, 2026 23w ago | 8-K | $11.60 $16.58 | ▲ +42.93% | ▲ +36.64% | $7.61 (−34.40%) |
Apr 30, 2026 25w ago | S-3/A | $9.65 $13.34 | ▼ −38.24% | ▼ −35.17% | $7.61 (+21.14%) |
Apr 23, 2026 26w ago | 8-K | $9.18 $15.00 | ▲ +63.40% | ▲ +58.38% | $7.61 (−17.10%) |
Apr 14, 2026 28w ago | 8-K | $11.10 $14.77 | ▲ +33.06% | ▲ +24.93% | $7.61 (−31.44%) |
Apr 10, 2026 28w ago | 8-K | $12.20 $14.77 | ▲ +21.07% | ▲ +12.14% | $7.61 (−37.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers